BeOne Medicines (BEIGF) Inventory (2017 - 2026)

BeOne Medicines (BEIGF) has 10 years of Inventory data on file, last reported at $681.6 million in Q1 2026.

• Inventory for Q1 2026 came in at $681.6 million, up 37.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $681.6 million (up 37.79% YoY), and the FY2025 annual result was $608.2 million, up 22.88% from the prior year.
• Inventory improved to $681.6 million in Q1 2026 per BEIGF's latest filing, from $608.2 million in the prior quarter.
• Over five years, Inventory peaked at $681.6 million in Q1 2026 and troughed at $245.6 million in Q1 2022.
• A 5-year average of $415.8 million and a median of $431.7 million in 2024 frame the typical range for Inventory.
• The sharpest annual moves came in 2022 and 2023: Inventory surged 236.6% in 2022, then rose 8.94% in 2023.
• A 5-year view of Inventory shows it stood at $282.3 million in 2022, then soared by 47.38% to $416.1 million in 2023, then advanced by 18.95% to $495.0 million in 2024, then advanced by 22.88% to $608.2 million in 2025, then advanced by 12.06% to $681.6 million in 2026.
• Business Quant data shows BEIGF's Inventory at $681.6 million in Q1 2026, $608.2 million in Q4 2025, and $531.7 million in Q3 2025.